Milestone Pharmaceuticals (MIST) News Today

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

$1.63

-0.12 (-6.86%)

(As of 04/18/2024 ET)

Source

Source	Headline
	Milestone® Pharmaceuticals to Present Data on Etripamil at the Preventative Cardiovascular Nursing Symposium finance.yahoo.com - April 17 at 1:05 PM
	Milestone® Pharmaceuticals to Present Data on Etripamil at the Preventative Cardiovascular Nursing Symposium globenewswire.com - April 17 at 8:00 AM
	Milestone Pharmaceuticals (NASDAQ:MIST) Stock Price Up 3.8% marketbeat.com - April 13 at 12:40 AM
	Milestone® Pharmaceuticals Announces Etripamil Data Demonstrating Patients’ Ability to Self-Manage Recurring PSVT, Presented at The American College of Cardiology Annual Meeting finance.yahoo.com - April 8 at 1:58 PM
	Milestone® Pharmaceuticals Announces Etripamil Data Demonstrating Patients' Ability to Self-Manage Recurring PSVT, Presented at The American College of Cardiology Annual Meeting globenewswire.com - April 8 at 11:36 AM
	Milestone® Pharmaceuticals to Present at the 23rd Annual Needham Healthcare Conference finance.yahoo.com - April 3 at 8:38 AM
	Milestone® Pharmaceuticals to Present Data on Etripamil at the American College of Cardiology and European Heart Rhythm Association Annual Conferences globenewswire.com - April 1 at 8:00 AM
	Milestone Pharmaceuticals Announces Resubmission of New Drug Application for Etripamil for Treatment in Paroxysmal Supraventricular Tachycardia finance.yahoo.com - March 28 at 10:18 AM
	Analysts Offer Insights on Healthcare Companies: Plus Therapeutics (PSTV) and Milestone Pharmaceuticals (MIST) markets.businessinsider.com - March 22 at 6:47 PM
	Milestone Pharmaceuticals (NASDAQ:MIST) Earns Buy Rating from HC Wainwright marketbeat.com - March 22 at 2:58 PM
	Milestone Pharmaceuticals’ Etripamil Nears Approval: A Strong Buy Recommendation markets.businessinsider.com - March 21 at 11:20 PM
	MIST Stock Earnings: Milestone Pharmaceuticals Misses EPS for Q4 2023 investorplace.com - March 21 at 2:05 PM
	Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Regulatory and Corporate Update globenewswire.com - March 21 at 7:14 AM
	Milestone Pharmaceuticals (NASDAQ:MIST) Price Target Lowered to $5.00 at Piper Sandler marketbeat.com - March 5 at 9:19 AM
	Milestone® Pharmaceuticals to Participate in a Corporate Panel Discussion at TD Cowen 44th Annual Health Care Conference globenewswire.com - February 29 at 4:01 PM
	Milestone Pharmaceuticals Announces Pricing of $30.0 Million Public Offering of Common Shares and Pre-Funded Warrants globenewswire.com - February 29 at 7:00 AM
	Milestone Pharma Shares Drop After Public Offering News marketwatch.com - February 28 at 10:27 PM
	Milestone Pharmaceuticals launches stock and warrants offering msn.com - February 28 at 10:27 PM
	Milestone Pharmaceuticals Announces Proposed Public Offering of Common Shares and Pre-Funded Warrants globenewswire.com - February 28 at 4:37 PM
	Milestone Pharmaceuticals Earns Buy Rating on Strong Regulatory and Financial Outlook markets.businessinsider.com - February 26 at 6:16 PM
	Why Milestone Pharmaceuticals (MIST) Stock Is Rising msn.com - February 26 at 1:16 PM
	Milestone Pharmaceuticals Announces Plan to Resubmit NDA for Etripamil for the Treatment of PSVT finance.yahoo.com - February 26 at 8:15 AM
	Milestone Pharmaceuticals Stock (NASDAQ:MIST) Insider Trades benzinga.com - February 21 at 7:51 PM
	Merrimack Pharmaceuticals to Get $225M Milestone Payment After FDA's Supplemental NDA Approval marketwatch.com - February 13 at 7:19 PM
	Milestone Pharmaceuticals Inc. (MIST) finance.yahoo.com - February 11 at 5:44 PM
	Novartis eyes 5% annual sales growth through 2028 reuters.com - January 31 at 8:18 AM
	Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Short Interest Update marketbeat.com - January 30 at 11:18 AM
	Dr. Ferrer BioPharma Awarded Winner at CPHI Pharmapack 2024 for Groundbreaking GentleMist Technology businesswire.com - January 25 at 6:27 PM
	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Milestone Pharmaceuticals Inc.- MIST stockhouse.com - January 20 at 12:25 PM
	Down -43.64% in 4 Weeks, Here's Why Milestone Pharmaceuticals (MIST) Looks Ripe for a Turnaround finance.yahoo.com - January 16 at 2:35 PM
	ROSEN, A LONGSTANDING LAW FIRM, Encourages Milestone Pharmaceuticals Inc. Investors to Inquire About Securities Class Action Investigation - MIST markets.businessinsider.com - December 30 at 1:43 PM
	Milestone Pharmaceuticals Stock (NASDAQ:MIST), Analyst Ratings, Price Targets, Predictions benzinga.com - December 28 at 12:30 PM
	Milestone Pharmaceuticals Stock (NASDAQ:MIST) Dividends: History, Yield and Dates benzinga.com - December 28 at 1:22 AM
	Milestone Pharmaceuticals Earns Buy Rating Amid Promising Clinical Trials and Market Potential markets.businessinsider.com - December 27 at 3:22 PM
	Milestone Pharma (MIST) Down on Regulatory Update for Etripamil finance.yahoo.com - December 27 at 3:22 PM
	ROSEN, A LEADING LAW FIRM, Encourages Milestone Pharmaceuticals Inc. Investors to Inquire About Securities Class Action Investigation – MIST businesswire.com - December 26 at 5:19 PM
	Milestone Pharma Receives Refusal To File Letter From FDA For NDA For Etripamil In PSVT Treatment markets.businessinsider.com - December 26 at 12:18 PM
	Why Is Heart Disease-Focused Milestone Pharmaceuticals Stock Plummeting Today? msn.com - December 26 at 12:18 PM
	Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) top owners are individual investors with 52% stake, while 34% is held by institutions finance.yahoo.com - December 26 at 7:18 AM
	Milestone Pharmaceuticals Receives Refusal to File Letter from U.S. FDA for New Drug Application for Etripamil in the Treatment of PSVT finance.yahoo.com - December 26 at 7:18 AM
	marketbeat.com - December 26 at 6:59 AM
	Milestone Pharmaceuticals to Present at the Piper Sandler 35th Annual Healthcare Conference finance.yahoo.com - November 21 at 7:52 AM
	U.S. Economic Outlook 2023: GDP and Interest-Rate Forecasts morningstar.com - November 17 at 8:08 AM
	Milestone Pharmaceuticals Third Quarter 2023 Earnings: US$0.45 loss per share (vs US$0.34 loss in 3Q 2022) finance.yahoo.com - November 15 at 8:24 AM
	Milestone Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Clinical and Corporate Updates finance.yahoo.com - November 13 at 7:06 AM
	Milestone Pharmaceuticals Presents Positive Results from ReVeRA Phase 2 Study of Etripamil in AFib-RVR at the American Heart Association Scientific Sessions 2023 finance.yahoo.com - November 11 at 1:09 PM
	Milestone Pharmaceuticals to Host Investor and Analyst Webcast to Review Data from ReVeRA Phase 2 Study of Etripamil in AFib-RVR finance.yahoo.com - November 7 at 8:28 AM
	Amanda Morningstar health.usnews.com - October 24 at 11:36 PM
	Milestone Pharmaceuticals Announces Submission of New Drug Application to the U.S. FDA for Etripamil finance.yahoo.com - October 24 at 8:29 AM
	Pleasing Signs As A Number Of Insiders Buy Milestone Pharmaceuticals Stock finance.yahoo.com - October 8 at 1:16 PM

Get Milestone Pharmaceuticals News Delivered to You Automatically

Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (Ad)

You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.

Click here to find out that this 8,788% cryptocurrency is.

MIST Media Mentions By Week

MIST Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

MIST
News Sentiment
▼
0.46

0.49
▲
Average
Medical
News Sentiment

MIST News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

MIST Articles
This Week
▼
3

1
▲
MIST Articles
Average Week

Get Milestone Pharmaceuticals News Delivered to You Automatically

Related Companies and Tools

Related Companies:

Headlines Tools:

This page (NASDAQ:MIST) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Milestone Pharmaceuticals (MIST) News Today

MIST Media Mentions By Week

MIST Media Sentiment

MIST News Coverage

Related Companies and Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info